Since the incidence of EML4-ALK is low in NSCLC patients, it is necessary to elucidate clinicopathological characteristics of the EML4-ALK fusion gene-positive lung cancer to improve screening efficiency. Here, ALK is linked to non-small cell lung carcinoma.